Alok Swaroop

5PUBLICATIONS
53CO-AUTHORS
Gene and molecular therapyTransplantation immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Dec 23, 2025
Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.

Alok Swaroop, Timothy Oh, Kristy Wolniak

|Feb 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.

Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy

|Jun 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Jia Ruan, Jasmine Zain, Brett Palmer

|Aug 21, 2021
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic Leukemia.

Jianping Li, Julia Hlavka-Zhang, Jonathan H Shrimp

Pageof 1

Frequent Collaborators

3 joint publications

Yasmin Abaza

1 joint publications

Julia Hlavka-Zhang

1 joint publications

Jonathan H Shrimp

1 joint publications

Jacob S Roth